MasterBrand, Inc. (MBC) Stock News

Hagens Berman is investigating Embecta Corp. for alleged securities law violations, claiming the company misrepresented the stability of its insulin pen needle business. Embecta's stock plummeted 57.8% after revealing significant revenue decline, slashing full-year EPS guidance by 43% and cutting its quarterly dividend by 93%. The class action lawsuit covers the period from November 25, 2025 to May 4, 2026, with a lead plaintiff deadline of August 17, 2026.

Rosen Law Firm is reminding Embecta Corp. investors who purchased stock between November 25, 2025 and May 4, 2026 of an August 17, 2026 deadline to join a securities class action lawsuit. The lawsuit alleges that Embecta made false and misleading statements about its fiscal results and guidance, particularly regarding its pen needle business, which it described as 'incredibly resolute' before missing expectations and cutting 2026 guidance.

Shareholder class action lawsuits have been filed against Embecta Corp. and Via Transportation Inc., with allegations of false statements and failure to disclose segment weakness and revenue guidance disruptions. Additionally, Holzer & Holzer, LLC announced an investigation into ADTRAN Holdings Inc. regarding potential federal securities law violations. Investors who suffered losses during the relevant periods are encouraged to contact the law firm.

Embecta Corp. faces a securities fraud class action lawsuit after its stock plummeted 57.8% on May 5, 2026, when the company revealed disappointing Q2 results and admitted to significant market softness in insulin pens and pen needles. Investors allege the company misrepresented the strength of its insulin pen portfolio prior to the announcement. The lead plaintiff deadline is August 17, 2026.

Rosen Law Firm is reminding investors who purchased Embecta Corp. common stock between November 25, 2025 and May 4, 2026 of the August 17, 2026 lead plaintiff deadline in an ongoing securities class action. The lawsuit alleges that Embecta made false and misleading statements about its fiscal results and guidance, particularly regarding its pen needle business, which it described as 'incredibly resolute' before missing expectations and cutting 2026 guidance.

Rosen Law Firm is notifying investors about multiple securities class action lawsuits. The primary focus is on Embecta Corp., where investors who purchased stock between November 25, 2025 and May 4, 2026 may be entitled to compensation. The lawsuit alleges that Embecta made false statements about its fiscal results and guidance, particularly regarding its pen needle business, which it described as 'incredibly resolute' before missing expectations and cutting 2026 guidance. The lead plaintiff deadline is August 17, 2026. Similar class actions are also mentioned for Calix, Inc. and Lucid Group, Inc.

Embecta Corp. (EMBC) faces a securities class action lawsuit for allegedly concealing material risks to its pen needle business. The company provided reassuring guidance in February 2026 but reported a shocking 61% sequential EPS decline in Q2 2026, with pen needle revenues suffering massive declines. Embecta slashed its full-year EPS guidance by 43% and cut its dividend by 93%, triggering significant shareholder losses.

Rosen Law Firm is soliciting investors who purchased shares of Embecta Corp., Nano-X Imaging Ltd., and Lucid Group, Inc. during specified periods to join securities class action lawsuits. The lawsuits allege that these companies made false or misleading statements regarding financial guidance and business performance. Investors with losses exceeding $100,000 are encouraged to secure counsel before the August 17, 2026 lead plaintiff deadline.

Embecta Corp. faces a securities fraud class action lawsuit after revealing a 14% revenue decline due to weakness in pen needle sales and lowering fiscal 2026 guidance on May 5, 2026. The stock plummeted 57.8% to $3.90 per share. Defendants are accused of making materially false statements and failing to disclose material adverse facts about the company's business and prospects during the Class Period (November 25, 2025 - May 4, 2026). The deadline to file a lead plaintiff motion is August 17, 2026.

A securities class action lawsuit has been filed against Embecta Corp. (NASDAQ: EMBC) alleging that the company made false and misleading statements about its financial guidance. Embecta's stock plummeted 57.8% on May 5, 2026, after the company disclosed a revenue decline of over 14% and cut its fiscal year 2026 guidance, primarily due to weakness in pen needle sales. The deadline to seek lead plaintiff status is August 17, 2026.

Embecta Corp. (EMBC) faces a securities class action lawsuit for allegedly concealing material risks to its pen needle business. The company provided reassuring guidance in February 2026 but reported a shocking 61% sequential EPS decline in Q2 2026, with pen needle revenues suffering massive declines. The company slashed full-year EPS guidance by 43% and cut its dividend by 93%, prompting investigations into whether management knew about revenue headwinds but failed to disclose them.

Law Offices of Howard G. Smith has announced securities fraud class action lawsuits against four publicly-traded companies: Embecta Corp., First Solar Inc., ZoomInfo Technologies Inc., and Peabody Energy Corporation. The lawsuits allege that defendants made false or misleading statements regarding business guidance, operational performance, and market conditions. Investors have until mid-to-late August 2026 to file lead plaintiff motions.

A securities fraud class action lawsuit has been filed against Embecta Corp. (NASDAQ:EMBC) after its stock plummeted 57.8% on May 5, 2026. The company allegedly misled investors about the strength of its insulin pen needle product portfolio, claiming resilience while facing significant competition and market softness. The disappointing Q2 2026 results revealed share loss in the pen needle category and led to a dividend reduction from $0.15 to $0.01 per share.

Rosen Law Firm announces a securities class action lawsuit against Embecta Corp., alleging the company made false and misleading statements about its fiscal results and pen needle business guidance. Investors who purchased EMBC stock between November 25, 2025 and May 4, 2026 may be entitled to compensation. The deadline to serve as lead plaintiff is August 17, 2026.

Embecta Corp. (EMBC) faces a securities class action lawsuit for allegedly concealing material risks to its pen needle business. The company provided reassuring guidance in February 2026 but reported a shocking 61% sequential EPS decline in Q2 2026, with pen needle revenues suffering massive declines. The company slashed its 2026 EPS guidance by 43% and cut its dividend by 93%, triggering significant shareholder losses.

Faruqi & Faruqi, LLP has filed a securities class action lawsuit against Embecta Corp. (NASDAQ: EMBC) alleging that the company made false and misleading statements about its pen needle business and financial guidance. On May 5, 2026, Embecta disclosed a revenue decline of over 14% versus guided flat to 2% decline, causing the stock to plummet 57.8% in a single day. Investors who purchased Embecta securities between November 25, 2025 and May 4, 2026 may be eligible to participate in the lawsuit, with the lead plaintiff deadline set for August 17, 2026.

Rosen Law Firm is soliciting investors who purchased shares of Embecta Corp. (EMBC), Zillow Group (ZG), and Barclays PLC (BCS) during specified periods to join securities class action lawsuits. The firm alleges that Embecta made false statements about its fiscal results and pen needle business guidance before missing expectations and cutting guidance. The lead plaintiff deadline for Embecta is August 17, 2026.

Embecta Corp. (EMBC) faces a securities class action lawsuit for allegedly misleading investors about the stability of its pen needle business. The company provided optimistic guidance in February 2026 but reported a 61% sequential EPS decline in Q2 2026, slashed full-year guidance by 43%, and cut its dividend by 93%, triggering a significant stock selloff. Investors are urged to report losses by August 17, 2026.

Class action lawsuits have been filed against Embecta Corp., Black Rock Coffee Bar, Inc., and First Solar, Inc. for allegedly making materially false statements and failing to disclose material adverse facts. Embecta faces allegations of misleading guidance and U.S. pen needle market weakness. Black Rock Coffee is accused of overstating expansion strategy and experiencing sales cannibalization. First Solar is alleged to have overstated its ability to manage U.S. tariff impacts. Lead plaintiff deadlines range from August 17-24, 2026.

Rosen Law Firm has filed a class action lawsuit against Embecta Corp. on behalf of investors who purchased common stock between November 25, 2025 and May 4, 2026. The lawsuit alleges that Embecta made false and misleading statements about its fiscal results and guidance, particularly regarding its pen needle business, which it described as 'incredibly resolute' before subsequently missing expectations and cutting 2026 fiscal guidance. Investors who purchased shares during this period may be entitled to compensation. The deadline to serve as lead plaintiff is August 17, 2026.

Rosen Law Firm has filed class action lawsuits against Embecta Corp. for allegedly making false statements about fiscal results and pen needle business performance, cutting 2026 guidance. The firm is also investigating claims against Zoetis Inc. and Disc Medicine Inc. Investors who purchased securities during specified periods may be eligible for compensation.

Rosen Law Firm has filed class action lawsuits against Embecta Corp., Phreesia, Inc., and America's Car-Mart, Inc. on behalf of investors who suffered losses. The Embecta lawsuit alleges the company made false statements about its fiscal results and pen needle business guidance, which proved unattainable. Investors who purchased shares during specified periods may be eligible for compensation.

Robbins LLP has filed a class action lawsuit against Embecta Corp. (EMBC) for allegedly misleading investors about its business prospects. The company failed to meet Q2 2026 guidance with a 14% revenue decline versus guidance of flat to 2% decline, primarily due to weakness in pen needle sales. The stock fell to $3.90 per share on May 5, 2026, following the disappointing earnings announcement.

Embecta Corp. (EMBC) faces a securities class action lawsuit for allegedly misleading investors about the stability of its pen needle business. The company provided positive guidance in February 2026 but reported a 61% sequential EPS decline in Q2 2026, slashed full-year guidance by 43%, and cut its dividend by 93%, triggering a massive stock selloff. Investors are being urged to report losses.

Rosen Law Firm has filed a class action lawsuit against Embecta Corp. on behalf of investors who purchased common stock between November 25, 2025 and May 4, 2026. The lawsuit alleges that Embecta made false and misleading statements about its fiscal results and guidance, specifically regarding its pen needle business, which it described as 'incredibly resolute' before missing expectations and cutting 2026 guidance. Investors who purchased during this period may be entitled to compensation. The deadline to serve as lead plaintiff is August 17, 2026.

A securities fraud class action has been filed against Embecta Corp. (NASDAQ: EMBC) for providing overwhelmingly positive statements while concealing poor fiscal results. The company touted strong pen needle business performance before missing guidance and cutting 2026 fiscal guidance. On May 5, 2026, Embecta revealed a 14% revenue decline and lowered full-year guidance, causing the stock to plummet 57.8% in a single day from $9.25 to $3.90 per share. Investors who purchased shares between November 25, 2025 and May 4, 2026 may be eligible to participate in the class action.

Embecta Corp. (EMBC) faces a securities class action lawsuit for allegedly misleading investors about the stability of its pen needle business. The company provided optimistic guidance in February 2026 but reported a 61% sequential EPS decline in Q2 2026, slashed full-year guidance by 43%, and cut its dividend by 93%, triggering a significant stock selloff. Investors are being urged to report losses as the investigation examines when management knew about revenue headwinds.

Law firm Kirby McInerney LLP is investigating Embecta Corp. following the company's May 5, 2026 earnings report that missed analyst expectations and included reduced full-year guidance. The announcement cited losses in pen needle products at a major customer and market softness in insulin pens. Embecta's stock price plummeted 58% from $9.25 to $3.90 per share on the news. The investigation seeks to determine if federal securities laws were violated.